Skip to main
MAZE

MAZE Stock Forecast & Price Target

MAZE Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Maze Therapeutics is an attractive investment due to their promising drug MZE829 that could potentially delay disease progression and reverse symptoms of chronic kidney disease and other conditions by inhibiting APOL1 pore formation and function. With potential accelerated approval and the ability to slow the progression of diabetes, there are strong financial prospects for the company. However, there may be concerns regarding competition and effectiveness, as well as a need for further research and genotyping to fully understand the impacts of the drug on individuals with chronic kidney disease.

Bears say

Maze Therapeutics is a clinical-stage biopharmaceutical company that is utilizing its Compass platform to develop precision medicines for renal, cardiovascular, and related metabolic diseases. However, their lead candidate MZE829 has a dual mechanism of action (disrupting pore assembly and blocking function) and targets the EC90 threshold, suggesting a higher ceiling for efficacy. While competition in the APOL1-mediated kidney disease market is increasing, Maze's rigorous PK/PD strategy and expansion beyond FSGS to include diabetic kidney disease and hypertensive CKD potentially positions them to capture a significant share of the market. However, time and the HORIZON trial will be the true test of MZE829's efficacy and potential "best-in-class" profile.

MAZE has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Maze Therapeutics Inc (MAZE) Forecast

Analysts have given MAZE a Buy based on their latest research and market trends.

According to 8 analysts, MAZE has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Maze Therapeutics Inc (MAZE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.